Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by barsaxon Feb 29, 2020 6:57pm

257 Views

Post# 30751887

Resverlogix needs to be at this conference

[url=https://https://404d0c7a-41d1-43f9-9a1b-795cb903c458.filesusr.com/ugd/a72e45_bd45edd035e243918fcf0ef5aa8dfca5.pdf][/url]

Heart in Diabetes Conference - New York City - June 26-28

go through the agenda...Prof Kausik Ray is speaking:

Epigentic Modification to Reduce CVD in People with DM Kausik Ray, MD

but there's a lot more....this stuff just screams out for RVX 208

I hope COVID - 19 doesn't affect NKF at the end of March

Bullboard Posts

Golden Minerals closes Yoquivo gold-silver project sale